Clinical trials: Small Cell Lung Carcinoma Extensive Disease
- Condition Small Cell Lung Carcinoma Extensive Disease
- Funder type Industry (pharma, biotech, devices)
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
- Trial name
- MERU (NCT03033511)
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 308 sites in United States, Australia and 39 more
- Volunteers
- 748 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.
- Trial name
- NCT00472771
- Testing
- INNO-206
- Where
- 7 sites in United States
- Sponsor
- CytRx
Small Cell Lung Carcinoma
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer.
- Trial name
- ARSENAL (NCT05683977)
- Testing
- durvalumab
- Where
- 34 sites in France
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.
- Trial name
- NCT04449861
- Testing
- Durvalumab plus chemotherapy
- Where
- 30 sites in China
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR)…
- Trial name
- IMPULSE (NCT02200081)
- Testing
- MGN1703, Standard of care
- Where
- 4 sites in Austria, Belgium and 2 more
- Volunteers
- 103 people
- Sponsor
- Mologen AG
Extensive-stage Small-cell Lung Cancer
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT07654400
- Testing
- BL-M14D1, Atezolizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Conditions
- Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05882058
- Testing
- BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
- Trial name
- NCT01237678
- Testing
- IMGN901, Carboplatin and Etoposide
- Where
- 48 sites in United States, Canada and 2 more
- Volunteers
- 181 people
- Sponsor
- ImmunoGen, Inc.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Small Cell Lung Carcinoma Extensive Disease
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab…
- Trial name
- CASPIAN (NCT03043872)
- Testing
- Durvalumab, Tremelimumab, Carboplatin
- Where
- 207 sites in United States, Argentina and 21 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Relapsed/Refractory Small Cell Lung Cancer
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
- Trial name
- NCT07325136
- Testing
- BMS-986525, Pumitamig
- Where
- 13 sites in United States, China and 4 more
- Volunteers
- 240 people
- Sponsor
- Bristol-Myers Squibb
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study of Ivonescimab in First-Line ES-SCLC
The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with…
- Trial name
- NCT07245446
- Testing
- Ivonescimab, Cadonilimab, AK117
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Small Cell
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
The purpose of the study is to determine whether the study drug ZK 219477 (also known as SH Y03757A) combined with cisplatin, is effective in the treatment of small cell lung cancer in patients who did not receive prior treatment…
- Trial name
- NCT00359359
- Testing
- Sagopilone (BAY86-5302, ZK 219477), Cisplatin
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Bayer
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Small Cell Lung Cancer
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC.
- Trial name
- NCT02913443
- Testing
- RO7051790
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche